Pricing
  1. JP-listed companies
  3. Financials
  4. Retained earnings

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRetained earnings (Million JPY)YoY (%)
Dec 31, 2025-899+14.19%
Dec 31, 2024-787-14.05%
Dec 31, 2023-916-57.42%
Dec 31, 2022-2,150-83.81%
Dec 31, 2021-13,280+8.67%
Dec 31, 2020-12,220+10.04%
Dec 31, 2019-11,105+17.03%
Dec 31, 2018-9,489+15.42%
Dec 31, 2017-8,221+12.05%
Dec 31, 2016-7,337+20.72%
Dec 31, 2015-6,078+16.89%
Dec 31, 2014-5,199

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat